A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyUpdates of mTOR inhibitorsThe mTOR signalling pathway in human cancerTargeting the mTOR signaling network for cancer therapyTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesSignal transduction inhibitors in treatment of myelodysplastic syndromesProtein kinase inhibitors against malignant lymphomaJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayPI3K/PTEN signaling in angiogenesis and tumorigenesisCurrent phase II clinical data for ridaforolimus in cancer.A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors.Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Targeting the translational machinery as a novel treatment strategy for hematologic malignanciesDegrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.The complexes of mammalian target of rapamycin.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Targeted therapy in lymphoma.8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraNew strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Novel therapeutics for aggressive non-Hodgkin's lymphoma.A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.mTORC1 is essential for leukemia propagation but not stem cell self-renewal.Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signalingLKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitroCytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.Molecular pathogenesis of mantle cell lymphoma.Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
P2860
Q21198871-3132CE95-3C9F-427C-B6E1-399CECBC6524Q24607170-9E2DAFA6-2FAD-478A-B599-8EB298655DC9Q24627306-B784A3FF-17A2-4F2F-BC04-759995A3A447Q24658334-52FE6F05-A9BD-41F8-BFC4-7A942A103CF3Q26829652-097742A8-14B7-4054-89DF-E4D96A5E8960Q26829903-438C81AD-C177-4D1E-8388-E4FF07A9A24AQ27024212-161C8348-C7B8-4EF4-9434-5F45BC761B4FQ28071388-4EAC7216-166D-47D7-9FF3-6E226272D7BAQ28382812-BD33F136-886B-4CA3-9809-3790DD63B7D1Q28383083-2752C37C-F196-4675-B4FF-ED336EA65FDAQ30662689-B4EAEA06-20F5-4AD0-A7EA-EAEA9EEC5A23Q33408918-C2BA5F45-6C12-4A28-86F9-082DD2D1E33EQ33424649-229CD2ED-3296-4669-8962-76F3CEC08C56Q33437313-89096A65-5C7A-4518-A9C1-066C9E232A80Q33442539-6FFCCC0E-48C1-49CC-A487-8D67E455DFEBQ33493174-192A729F-C4F2-4DEB-97DD-59A25074FC2AQ33747291-8C66B76A-2D59-46C3-921E-079B9BA14E29Q33832937-550A5E53-AAE2-4312-BC1A-FDFCC14ED312Q34024558-F01967EB-195C-41B4-AB3D-A8D8CAC7EFC5Q34116818-3E2A24F9-C878-41A2-A677-73506093088AQ34129360-421FB543-2979-4968-B71D-97752D0C9825Q34260622-B828909F-BA11-4149-BA18-C866BBB325FFQ34413686-25513C22-0CAD-443D-90AC-E95A9B8D0B17Q34541728-441BEC5C-39E9-4395-A974-D2FA264795FDQ34568868-286EE3AE-5F90-46C8-880B-12F38734C142Q34715598-E51D574F-0E7A-4C0F-A34C-DEAF7FC83291Q35111768-72E0CEE9-B6BD-40AC-8ACE-47BDD638F8DBQ35138166-63334C7C-5378-4B28-92EC-71009EE79536Q35679353-93456439-2644-4152-A019-9A638DE80437Q35740894-3430836B-944F-4347-89C3-A6053F35E6A3Q35854816-F446F14F-E050-4EC9-84EC-25B38AB9A488Q36005418-EEE7394B-4E7E-4A06-B2AB-AD59E91EDF9CQ36006981-9B292E2A-0F49-4A5B-A055-03ED631450B4Q36034229-477EE4A3-A107-4C53-8E7E-70A333BA204BQ36105149-E4BCD863-E009-4AEC-9355-AE0E1B4493D3Q36204972-42FAC8F5-F3C4-4E7C-934C-C0E620846CCBQ36214081-17DFE988-76FF-457F-8A53-A81EBC8EE010Q36275411-18C4D13C-5FBE-41AA-843F-3C3D1B29A6D7Q36290246-8B5EEB97-F0A2-4ABD-B380-89CABC59C68DQ36352535-88370AFC-1491-4AC3-B542-840F9C0EC2DD
P2860
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@ast
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@en
type
label
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@ast
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@en
prefLabel
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@ast
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@en
P2093
P1476
A phase 2 clinical trial of de ...... tory hematologic malignancies.
@en
P2093
Camille L Bedrosian
David A Rizzieri
Eric Feldman
Francis J Giles
John F Dipersio
Nashat Gabrail
Roger Strair
Victor M Rivera
Wendy Stock
P304
P356
10.1158/1078-0432.CCR-07-1372
P407
P577
2008-05-01T00:00:00Z